Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies

被引：0

作者：

Le, X. ^{[1
]}

Prelaj, A. ^{[2
]}

Baik, C. ^{[3
]}

Tchekmedyian, N. ^{[4
]}

Leu, S. ^{[5
]}

Bhat, G. ^{[5
]}

Heymach, J. V. ^{[1
]}

Cornelissen, R. ^{[6
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Ist Nazl Tumori Milano Fdn IRCCS, Milan, Italy

[3] Seattle Canc Ctr Alliance, Seattle, WA USA

[4] City Hope Natl Med Ctr, Irvine, CA USA

[5] Spectrum Pharmaceut, Irvine, CA USA

[6] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

HER2; exon20; poziotinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA13.09

引用

页码：S147 / S148

页数：2

共 50 条

[21] High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
Le, X.
Sun, S.
Haura, E.
Bertino, E.
Baik, C.
Mamdani, H.
Leu, S.
Thiagalingam, A.
Kokhreidze, J.
Lebel, F.
Socinski, M. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1084 - S1085
[22] A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
Lathrop, K.
Lucas, J.
Vacirca, J. L.
Bhat, G.
Choi, M. R.
Naughton, M.
CANCER RESEARCH, 2017, 77
[23] Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
Sacher, A.
Le, X.
Cornelissen, R.
Shum, E.
Suga, J.
Socinski, M.
Molina, J. R.
Haura, E.
Clarke, J.
Bhat, G.
Lebel, F.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2021, 32 : S15 - S15
[24] Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing
Robichaux, Jacqulyne P.
Elamin, Yasir Y.
Tan, Zhi
Negrao, Marelo Vailati
Routbort, Mark
Roeck, Brent
Li, Shuai
Liu, Shengwu
Chen, Ting
Ahnert, Jordi Rodon
Diao, Lixia
Nilsson, Monique B.
Zhang, Shuxing
Yang, Zane
Wang, Jing
Meric-Bernstam, Funda
Wong, Kwok-Kin
Heymach, John V.
CANCER RESEARCH, 2018, 78 (13)
[25] Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
Pandey, Apurva
Brufsky, Adam M.
CLINICAL BREAST CANCER, 2019, 19 (01) : E7 - E11
[26] Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations
Chu, T.
Li, J.
Xie, M.
Zhao, R.
Qiang, H.
Chang, Q.
Qian, J.
Lu, H.
Shen, Y.
Han, Y.
Su, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S628
[27] Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, Iosune
Mezquita, Laura
Gil-Bazo, Ignacio
Planchard, David
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148
[28] JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC
Yu, Mi Ra
Yun, Mi Ran
Lee, Jii Bum
Lee, Ji Yun
Aum, So Won
Choi, Su Jin
Park, Ju Yeon
Oh, Seung Yeon
Lee, Eun Ji
Duggirala, Krishna Babu
Lee, Kwangho
Hong, Min Hee
Lim, Sun Min
Jo, Anna
Seah, Ethan
Kim, Choonok
Cho, Byoung Chul
CANCER RESEARCH, 2023, 83 (07)
[29] A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer
Yang, Zandong
Tchekmedyian, Nishan
Chu, David T.
Reddy, Guru
Bhat, Gajanan
Socinski, Mark A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Efficacy and safety of sunvozertinib in treatment naive NSCLC patients with EGFR exon20 insertion mutations
Xu, Yan
Yang, James Chih-Hsin
Chiu, Chao-Hua
Hsu, Ping-Chih
Mitchell, Paul
Chang, Chia Lun
John, Tom
Bazhenova, Lyudmila
Kim, Tae Min
Yip, Ching Wan
Wang, Mengzhao
Janne, Pasi A.
Zhou, Caicun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →